tbuckley/cabot-search huggingface dataset:
GENE-60. THE EPITRANSCRIPTOMIC CODE IN LGG: METABOLICALLY REPROGRAMMED IDH-MUTANT GLIOMAS ALTER tRNA MODIFICATION LANDSCAPE
Authors: Chantal Scheepbouwer, Kayla Borland, Ernesto Aparicio, Heleen Verschueren, Laurine Wedekind, Jip Ramaker, Branko Misovic, Mathilde CM Kouwenhoven, David Noske, Peter Vandertop, Pieter Wesseling, Tom Wurdinger, Michael Hackenberg, Stefanie Kellner, Danijela Koppers-Lalic
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Diffuse lower grade gliomas (LGGs) are generally slow growing primary central nervous system tumors that occur in early adult life. The prevalence of isocitrate dehydrogenase (IDH) mutations is high in LGG, and induces excess production of the oncometabolite 2-hydroxyglutarate (2-HG). These gain-of-function mutations play a key role in promoting metabolic reprogramming of the cancer cell that affects activity of α-KG dependent demethylases. Inhibition of DNA demethylase activity leads to glioma with a CpG island methylator phenotype (G-CIMP). Whether the activity of RNA demethylases and methylation status of tRNAs in LGG are modulated by changes in IDH-status is unknown. AIM: To investigate whether IDH mutations play a role in reprogramming of tRNA modifications in adult glioma. MATERIALS AND METHODS We combined small RNAseq and LC-MS/MS analysis to identify distinct tRNA processing patterns and methylation signatures in LGG tissues. To address important experimental bottlenecks that limit RNAseq-based detection of tRNA and possibly other modified small noncoding RNAs, we employed a tailored small RNAseq method with validation of specific methylation sites by mass-spectrometry. RESULTS Our customized small RNAseq approach yielded &gt;100 fold increase in sequencing reads per tRNA type, thereby dramatically improving tRNA detection when compared to currently used small RNAseq approaches. Moreover, LC-MS/MS analysis revealed a higher abundance of modified nucleosides in tRNA from IDH-mutant LGG compared to IDH-wildtype LGG. Analysis of tRNA from IDH-mutant and IDH-wildtype LGG using the combination of our tailored small RNAseq and LC-MS/MS methodology demonstrated strong differential tRNA expression, tRFs processing and tRNA methylation. CONCLUSION We described an approach that makes use of tailored small RNA sequencing combined with mass-spectrometry that enables insights into cancer driven alterations in tRNA methylation patterns and differential tRNA processing signatures. Our data implies that tumor metabolic reprogramming deregulates tRNA methylation, contributing to an altered epitranscriptomic code in IDH-mutant LGG.
Thrombotic Thrombocytopenic Purpura
Authors: Hau C. Kwaan
Journal: JAMA (1982)

Though thrombotic thrombocytopenic purpura (TTP) is not a common disorder, having an estimated annual incidence of one per million population, it merits attention.<sup>1</sup>First, it afflicts those in the prime of life between the third and fourth decade. Second, it generally runs a fulminant course with mortality in excess of 8096. Third, the recent introduction of plasma infusion and plasma exchange as a therapeutic mode significantly improves the outlook, giving a response rate of 70% to 90%. Originally described by Moschcowitz<sup>2</sup>in 1925 as an "acute febrile pleiochromic anemia associated with the presence of widespread microvascular occlusive thrombi," the etiology of TTP is still unknown, and the nature of the microvascular thrombotic lesion has been the object of many studies. Throughout the body, short segments of small arterioles and capillaries are partially or completely occluded by hyaline thrombi. Histochemical, immunologic, and ultrastructural findings indicate that the hyaline material
Disease Modeling and Phenotype Rescue Using Inducible Pluripotent Stem Cells from Patients with Diamond-Blackfan Anemia
Authors: Senthil Velan Bhoopalan, Min-Joon Han, Steven Ellis, Harry Lesmana, Jeremie H. Estepp, Yoonjeong Jang, Mitchell J. Weiss, Marcin W. Wlodarski
Journal: Blood (2019)
Identification of Novel Immune Cell Populations in Lenalidomide Refractory Relapsed Multiple Myeloma Patients Treated with Pomalidomide and Low Dose Dexamethasone
Authors: Anna Kalff, Tiffany Khong, Malarmathy Ramachandran, Sam Norton, Andrew Mitchell, John Reynolds, Hang Quach, P Joy Ho, Noemi Horvath, Peter Mollee, Nola Kennedy, Roslyn Kemp, Andrew Spencer
Journal: Blood (2019)
Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer
Authors: Robert L. Coleman, Nick M. Spirtos, Danielle Enserro, Thomas J. Herzog, Paul Sabbatini, Deborah K. Armstrong, Jae-Weon Kim, Sang-Yoon Park, Byoung-Gie Kim, Joo-Hyun Nam, Keiichi Fujiwara, Joan L. Walker, Ann C. Casey, Angeles Alvarez Secord, Steve Rubin, John K. Chan, Paul DiSilvestro, Susan A. Davidson, David E. Cohn, Krishnansu S. Tewari, Karen Basen-Engquist, Helen Q. Huang, Mark F. Brady, Robert S. Mannel
Journal: New England Journal of Medicine (2019)

Secondary surgical cytoreduction in women with platinum-sensitive, recurrent epithelial ovarian, primary peritoneal, or fallopian-tube ("ovarian") cancer is widely practiced but has not been evaluated in phase 3 investigation.
Altered Structure and Function of Mesenchymal Stromal Cell-Derived Extracellular Matrix in MDS Can be Restored By Luspatercept
Authors: Manja Wobus, Anna Mies, Valentina Magno, Cindy Welzel, Susann Winter, Friedrich Stoelzel, Carsten Werner, Martin Bornhaeuser, Uwe Platzbecker
Journal: Blood (2019)
Moving Toward Evidence-Based Policy
Authors: Atheendar S. Venkataramani, Kristen Underhill, Kevin G. Volpp
Journal: JAMA (2019)

This Viewpoint emphasizes the value of randomized evaluation of policies and programs designed to improve health behaviors, health outcomes, and health care delivery, and articulates preconditions that appear to be essential for the practice to become more of a standard in policy implementation.
Brentuximab Vedotin (BV) and Lenalidomide (Len) in Relapsed and Refractory (r/r) Cutaneous (CTCL) and Peripheral (PTCL) T-Cell Lymphomas; A Planned Interim Analysis of Phase II Trial
Authors: Basem M. William, Ying Huang, Amy Johnson, Jonathan E Brammer, John C. Reneau, Joseph Maakaron, Ruth Larbi, Cara Grantier, Corinne Hoffman, Sabarish Ayyappan, Robert A Baiocchi, Narendranath Epperla, Beth A. Christian, Lapo Alinari, Kami J. Maddocks, Catherine Chung
Journal: Blood (2019)
RBTT-03. USE OF VIRTUAL REALITY ENVIRONMENTS TO IMPROVE SELF-REPORTED DISTRESS, MOOD DISTURBANCE AND OVERALL SYMPTOM BURDEN USING CORRELATIVE STRESS BIOMARKERS IN PRIMARY BRAIN TUMOR (PBT) PATIENTS
Authors: Amanda King, Nicole Leggiero, Alvina Acquaye, Elizabeth Vera, Sonja Crandon, Mark Gilbert, Terri Armstrong
Journal: Neuro-Oncology (2019)

Abstract Approximately 20% of PBT patients experience moderate-severe distress at the time of neuroimaging &amp; diagnostic evaluation, which can adversely impact their psychological health and ability to tolerate oncologic therapies. Virtual reality (VR) technology is increasingly being utilized in clinical populations with demonstrated improvement in self-reported pain, anxiety, and distress, though little is known about the biological pathways involved. We hypothesize that VR can improve distress through a combination of distraction and promotion of the relaxation response, both of which could blunt activity of physiological stress pathways. The purpose of this study is to assess the effect of VR breathing and relaxation scenarios on self-reported acute and long-term distress incorporating correlative stress biomarkers, as well as assessing long-term effects on mood disturbance and overall symptom burden. This is a phase 2 experimental pre-post design with a sample size of 100 PBT patients, stratified into low and high distress groups. Self-reported measures include the Distress Thermometer, PROMIS Anxiety and Depression Short Forms, and the MD Anderson Symptom Inventory Brain Tumor instrument. Correlative stress biomarkers include salivary cortisol and dehydroepiandrosterone-sulfate (DHEA-S), representing hypothalamic-pituitary-adrenal (HPA) axis activity, and salivary alpha amylase (sAA) and heart rate, representing activity of the sympathetic-adrenal-medullary (SAM) system. Baseline and post-intervention assessments will be taken surrounding a 5 to 10 minute VR experience in clinic, with repeat assessments 1 week later and at the next clinic appointment. Anticipated outcomes include a decrease in self-reported acute and remote distress with correlative decrease in stress biomarkers, as well as improvement of mood disturbance and overall symptom burden. VR has the potential to help PBT patients improve self-management of their psychological symptoms, potentially enhancing their tolerance of oncologic therapies and overall quality of life. Additionally, the benefits of this intervention may have broad applicability to other cancer patient populations.
Stag2 Regulates Hematopoietic Differentiation and Self-Renewal through Alterations in Gene Expression and Topological Control
Authors: Aaron D Viny, Robert L Bowman, Yu Liu, Vincent-Philippe Lavallee, Shira Eisman, Wenbin Xiao, Benjamin H Durham, Anastasia Navitski, Jane Park, Stephanie Braunstein, Besmira Alija, Abdul Karzai, Isabelle S. Csete, Matthew Witkin, Elham Azizi, Timour Baslan, Christopher J. Ott, Dana Pe'er, Job Dekker, Richard Koche, Ross L. Levine
Journal: Blood (2019)
The IRE1-XBP1s Pathway Impairment Underpins NK Cell Dysfunction in Hodgkin Lymphoma, That Is Partly Restored By PD-1 Blockade
Authors: Karolina Bednarska, Jay Gunawardana, Frank Vari, Qingyan Cui, Gayathri Thillaiyampalam, Samantha Stehbens, Sally Mujaj, Jamie Nourse, Alexandre Cristino, Maher K. Gandhi
Journal: Blood (2019)
Allogeneic Cord Blood Regulatory T Cells Can Prevent Graft Vs. Host Disease and Preserve Graft Vs Leukemia Effect: Update on Phase I/II Clinical Trial
Authors: Ke Zeng, Hongbing Ma, Uday Popat, Yago Nieto, Stefan O. Ciurea, Amanda L. Olson, Mi-Ae Lyu, Meixian Huang, Mitsutaka Nishimoto, Muzaffar H. Qazilbash, Jennifer D Ramos, Elizabeth J. Shpall, Richard E. Champlin, Simrit Parmar, Borje S Andersson
Journal: Blood (2019)
Fetal Hemoglobin Measurement per Red Blood Cell Provides Biological and Clinical Protective Thresholds
Authors: Nicolas Hebert, Rakotoson Marie Georgine, Gwellaouen Bodivit, Etienne Audureau, Nadia Oubaya, Sadaf Pakdaman, Mehdi Sakka, Gaetana Di Liberto, Philippe Chadebech, Benoît Vingert, France Pirenne, Frédéric Galactéros, Marie Cambot, Pablo Bartolucci
Journal: Blood (2019)
The Typhus Group of Fevers
Authors: A. Felix
Journal: BMJ (1942)

The " typhus group of fevers," comprising a number of different varieties of the disease, is now firmly established.Typhus researches during the past few years have revealed the occurrence of typhus-like diseases in many parts of the world.Not a few endemic diseases of various tropical and subtropical countries, some of which had long been known under the label " unclassed fevers," have now been recognized as members of the typhus fever group.This recent development is mainly due to the application of serological and immunological methods to the study of these diseases.The so-called Weil-Felix reaction has pro- vided in almost every instance the 'first evidence of the generic relationship of the unknown disease, to classical louse-borne typhus, and thus opened the way for the experimental study which has led to the demonstration of the corresponding rickettsia.Some of the best-known instances of this sequence of events are: the endemic typhus of the United States of America (Maxcy and Havens, 1923); the tropical' typhus of the Federated Malay States (Fletcher and Lesslar, 1925); the " fievre exanthematiqiie' of Marseilles, and " fibvre boutonneuse " of Tunis (Buirnet and
Collection and Processing of Bone Marrow at 3% Oxygen Significantly Alters the Manifestation of Aged Mouse Hematopoietic Stem Cell Phenotype
Authors: Maegan L. Capitano, Scott Cooper, Bin Guo, Xinxin Huang, Carol Sampson, Safa Mohamad, Edward F. Srour, Christie M. Orschell, Hal E. Broxmeyer
Journal: Blood (2019)
Cost per Progression Free Survival (PFS) of Daratumumab, Elotuzumab, Carfilzomib and Ixazomib Combinations with Lenalidomide/Dexamethasone (DRd, ERd, KRd, IRd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Authors: Pamela Santana, Ricardo Saad, Adrielle Kolanian, Cyntia Fioratti, Marcela Junqueira, Tassia Decimoni
Journal: Blood (2019)
Clinical Features of Pediatric Acute Myeloid Leukemia with TP53 and CDKN2A/2B copy Number Alterations
Authors: Yusuke Hara, Tomohiko Taki, Genki Yamato, Kenichi Yoshida, Yusuke Shiozawa, Norio Shiba, Taeko Kaburagi, Yuichi Shiraishi, Kentaro Ohki, Machiko Kawamura, Manabu Sotomatsu, Hirokazu Arakawa, Hidemasa Matsuo, Akira Shimada, Tsutomu Toki, Nobutaka Kiyokawa, Daisuke Tomizawa, Takashi Taga, Etsuro Ito, Keizo Horibe, Satoru Miyano, Seishi Ogawa, Souichi Adachi, Yasuhide Hayashi
Journal: Blood (2019)
Targeting eIF4A Using MZ-735 Potently Induces Cell Death in Lymphoma Cells and Rapidly Represses mRNA Translation at the Global Level and in C-MYC and Other Oncogenes
Authors: Ipsita Pal, Yu Ri Kim, Sohani Das Sharma, Prabhjot S. Mundi, Andre M. Grilo, Luke E Berchowitz, Mingzhao Zhu, Hull G. Kenneth, Daniel Romo, Owen O'Connor, Marko Jovanovic, Changchun Deng
Journal: Blood (2019)
PRAME Expression Is Correlated with Treatment Outcome and Specific Features of the Tumor Microenvironment in Classical Hodgkin Lymphoma
Authors: Katsuyoshi Takata, Lauren C. Chong, Avinash Thakur, Tomohiro Aoki, Anja Mottok, Elizabeth Chavez, Pedro Farinha, Graham W Slack, Pamela Hoodles, Sohrab P Shah, David W. Scott, Christian Steidl
Journal: Blood (2019)
TMIC-57. PRO-TUMORAL EFFECTS OF INTRA-TUMORAL NEUTROPHILS IN THE GLIOBLASTOMA MICROENVIRONMENT
Authors: Sumedh Shah, Garima Yagnik, Alan Nguyen, Harsh Wadhwa, Jordan Spatz, Michael Safaee, Justin Cheng, Manish Aghi
Journal: Neuro-Oncology (2019)

Abstract While macrophage enrichment and lymphocyte depletion have been described in glioblastoma, intratumoral neutrophils and their effect on glioblastoma have been under-characterized. While tumor-associated neutrophils (TANs) were initially regarded as passive bystanders due to their short-lived nature, investigation of TANs in other cancer types revealed pro-tumoral roles. Therefore, we sought to characterize TANs in the glioblastoma microenvironment using transcriptomic analysis and define their oncologic effects. Flow cytometric analysis of patient samples for neutrophils (CD11b+/CD15+/CD66b+) revealed higher percentages of TANs in glioblastoma compared to low-grade gliomas (1.76% [n=13] vs. 0.33% [n=6], p=0.03). Using the Transwell migration assay with glioblastoma tumor conditioned-media (CM), we found that recruitment of circulating neutrophils to tumor sites is mediated by leukotriene-B4 chemoattraction and that this interaction can be blocked with the addition of LtB4 receptor antagonist, LY293111. TANs were morphologically activated, unlike circulating neutrophils from GBM patients (P&lt; 0.05) and, while not intravascular, were close to blood vessels. We performed single-cell RNA sequencing of isolated TANs and found a distinct transcriptomic profile relative to circulating neutrophils from these patients, particularly upregulated osteopontin. Osteopontin concentration was significantly higher in TAN CM than in patient-matched peripheral blood neutrophil CM (3.2ng/mL [n=3] vs. 0.02ng/mL [n=3], p&lt; 0.05). Because osteopontin is linked to GBM stem cell-like phenotype maintenance and TANs localized to the perivascular niche where GBM stem cells reside, we investigated TAN-GBM stem cell interactions and osteopontin as a potential mediator. We found TAN CM increased proliferation and stem cell markers (Nanog, Oct4, Sox2) of stem cell-containing GBM neurospheres (p&lt; 0.01). These effects were blocked by osteopontin-neutralizing antibodies (p&lt; 0.01). Our work defines neutrophil-mediated pro-tumoral effects and their mechanisms and identifies a novel approach to target GBM stem cells—by disrupting the immune cell mediators that create their supportive microenvironment in the perivascular niche.
Immunophenotype Drift of Residual Plasma Cells Indicates Therapeutic Response and Prognosis in Multiple Myeloma
Authors: Chenxing Du, An Gang, Yan Xu, Xuehan Mao, Yuting Yan, Jiahui Liu, Huishou Fan, Weiwei Sui, Shuhui Deng, Li Zengjun, Jiawei Zhao, Shuhua Yi, Dehui Zou, Lugui Qiu
Journal: Blood (2019)
Treatment of Recurrent Herpes Simplex
Authors: M. Duncan
Journal: BMJ (1964)

those listed which give considerable force to the belief that this substance is a most useful therapeutic agent in the treatment of the iso- lated attack, both in the eye and on the skin.It would be a pity if your readers were led to the supposition that this substance should not at least be tried when dealing with such lesions.I would like to point out how important it is that the correct regimen is adhered to.In many cases my colleagues have approached me about the apparent ineffectiveness of the drug.On inquiry it has appeared that their notions of both the indications and administration have been somewhat astray.It should further be borne in mind that it is essential that treatment begin at the very earliest stage of the disease.It is hardly rational to expect much effect from any antiviral agent when the full tissue picture has developed.One might per- haps except the cornea and its own rather individual circumstances.-Iam, etc., Brighton.
Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) after CD19-Directed Chimeric Antigen Receptor T-Cell Therapy (CAR-T) for Large B-Cell Lymphoma: Predictive Biomarkers and Clinical Outcomes
Authors: Noa G. Holtzman, Soren M. Bentzen, Vivek Kesari, Ali Bukhari, Firas El Chaer, Elizabeth Hutnick, Kathleen Ruehle, Natalie Gahres, Neil Porter, Carl Shanholtz, Mehmet Hakan Kocoglu, Ashraf Z. Badros, Babak Saboury, Jean A. Yared, Nancy M. Hardy, Aaron P. Rapoport, Saurabh Dahiya
Journal: Blood (2019)
In Vivo reconstruction of Human Erythropoiesis with Circulating Mature Human RBCs in Humanized Liver Mistrg Mice
Authors: Yuanbin Song, Liang Shan, Rana Gbyli, Wei Liu, Xiaoying Fu, Xiaman Wang, Ashley Qin, Amisha Patel, Yimeng Gao, Toma Tebaldi, Giulia Biancon, David Urbonas, Jonathan Alderman, Stephanie Halene, Richard Flavell
Journal: Blood (2019)
Phase I Dose Escalation Study of Radiotherapy and Durvalumab (MEDI4736) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): The RaDD Study
Authors: Eliza A Hawkes, Kate Manos, Geoff Chong, Jodie Palmer, Michael MacManus, Colm Keane, Andrew Scott, Jake Shortt, David Ritchie, Leonid Churilov, Laura Johnston, Tom Witkowski, Allison Barraclough, Sze-Ting Lee, Wendi Lin, Rachel Koldej, Richard Khor
Journal: Blood (2019)
Adipsin preserves beta cells in diabetic mice and associates with protection from type 2 diabetes in humans
Authors: Nicolás Gómez-Banoy, J. Sawalla Guseh, Ge Li, Alfonso Rubio-Navarro, Tong Chen, BreAnne Poirier, Gregory Putzel, Carolina Rosselot, Maria A. Pabón, João Paulo Camporez, Vijeta Bhambhani, Shih-Jen Hwang, Chen Yao, Rachel J. Perry, Sushmita Mukherjee, Martin G. Larson, Daniel Levy, Lukas E. Dow, Gerald I. Shulman, Noah Dephoure, Adolfo Garcia-Ocana, Mingming Hao, Bruce M. Spiegelman, Jennifer E. Ho, James C. Lo
Journal: Nature Medicine (2019)
Review: In multiepisode schizophrenia, most antipsychotic drugs improve symptoms; adverse effects vary by drug
Authors: Brian Budenholzer
Journal: Annals of Internal Medicine (2019)

Source Citation Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394:939-51. 31303314
Characterizing Autoimmune Hemolytic Anemia in RAG Deficiency
Authors: Kevin Wu, Jocelyn Farmer, Boglarka Ujhazi, Emma Westermann-Clark, Savic Sinisa, Sargur Ravishankar, Karin Chen, Dutmer Cullen, Maria G Kanariou, Mehdi Adeli, Paolo Palma, Carmem M. S. Bonfim, Evangelia Lycopoulou, Beata Wolska-Kusnierz, Dbaibo Ghassan, Jack Bleesing, Despina Moshous, Benedicte Neven, Scheutz Catharina, Geha Raif, Luigi Notarangelo, Maurizio Miano, David K. Buchbinder, Krisztian Csomos, Jolan Walter
Journal: Blood (2019)
GENE-26. HOST GENETIC VARIATIONS IN MACROPHAGE MIGRATION INHIBITOR FACTOR CONFER WORSE PROGNOSIS IN GLIOBLASTOMA
Authors: Balint Otvos, Matthew Grabowski, Tyler Alban, Joshua Golubovsky, Chase Neumann, Anja Rabjlenovic, Defne Bayik, Adam Lauko, Richard Bucala, Michael Vogelbaum, Justin Lathia
Journal: Neuro-Oncology (2019)

Abstract Genetic and systemic prognostic factors have been identified in glioblastoma (GBM) that correlate with survival, but patient-specific genomic risk factors that impact prognosis or response to immunotherapies have not been elucidated. GBM promotes an immune suppressive microenvironment via many mechanisms including the production of macrophage migration inhibitory factor (MIF) by GBM cancer stem cells, which activates myeloid derived suppressor cells (MDSCs). Increased circulating and intracranial MDSCs as well as intratumoral MIF expression in GBM patients portend a worse overall prognosis. Endogenous MIF expression is dependent on two genetic microsatellite loci: single nucleotide polymorphisms (SNPs) and CATT repeats within the promoter. To determine whether these genetic variations were linked to GBM development and/or prognosis, we assessed peripheral nucleated blood from 520 GBM patients for the MIF SNPs and CATT repeats. MIF microsatellite frequencies were similar between the normal population and GBM patients indicating loci variability was not a risk factor for GBM development. However, newly diagnosed IDH wild-type GBM patients with a minor allele SNP who received standard of care therapy had a 3.1 month shorter progression free survival (PFS), and a 4.3 month shorter overall survival (OS) when compared to patients with two major allele SNPs. This association was seen also with the CATT-repeat analyses. Furthermore, in a multivariate analysis for PFS that included age, sex, Karnofsky performance status, MGMT methylation status, 1p/19q co-deletion, and SNP status as covariates, only age and SNP status were independently associated with shorter PFS. Taken together, patients with variant MIF microsatellite loci experienced shorter PFS and decreased OS compared to those with the most common loci. These results are currently being validated in a separate 1700 patient cohort with the intent of understanding how MIF expression influences myeloid populations within the GBM microenvironment and then developing novel peripheral GBM screening markers for aggressiveness.
Genetic Characteristics and Outcomes By Mutation Status in a Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, High-Risk/Secondary Acute Myeloid Leukemia (AML)
Authors: R. Coleman Lindsley, Christopher J. Gibson, H. Moses Murdock, Richard M. Stone, Jorge E. Cortes, Geoffrey L. Uy, Tara L. Lin, Ellen K. Ritchie, Thomas Prebet, Robert J. Ryan, Stefan Faderl, Jeffrey E. Lancet
Journal: Blood (2019)
P2.24 Lung Immune Prognostic Index in Patients with Non-small Cell Lung Cancer Treated with Either Chemo or Immunotherapy
Authors: F. Barrón, B. Mota, L.A. Ramírez Tirado, L. Zatarain Barron, D. Lopez, M.P. Peralta Álvarez, O. Arrieta
Journal: Journal of Thoracic Oncology (2019)
APOBEC3B Induction Following DNA Damage Response Modulates the Survival and Treatment Response in Human Multiple Myeloma
Authors: Lijie Xing, Jiye Liu, Yuyin Li, Liang Lin, Kenneth Wen, Shih-Feng Cho, Tengteng Yu, Gang An, Lugui Qiu, Nikhil C. Munshi, Kenneth C. Anderson, Yu-Tzu Tai
Journal: Blood (2019)